As per Data Bridge Market Research analysis, the global haloperidol market was valued at USD 628.0 million in 2025 and is projected to reach USD 879.5 million by 2033, growing at a CAGR of 4.30% from 2026 to 2033.
The market is experiencing steady growth driven by haloperidol's sustained role as a low-cost, well-established first-generation antipsychotic used across schizophrenia management, acute psychiatric emergency care, and hospital agitation and delirium protocols.
Persistently high global schizophrenia and psychotic disorder prevalence, combined with the drug's continued affordability relative to newer atypical antipsychotics, continues to sustain demand, even as periodic manufacturing discontinuations of branded injectable formulations create localized supply challenges that generic manufacturer continue to help address.
